First-in-Class Host-Directed Therapeutic Developed Through the SCF–SEP Platform

A New Therapeutic Class for Systemic Immune–Metabolic Dysregulation

AHREX-101 is a first-in-class stress-conditional AHR governance modulator developed by SCF Biotech through the Selective Evolutionary Pressure (SEP) discovery platform within the Synergistic Compatibility Framework (SCF).

Unlike conventional AHR ligands that activate toxicant-like signaling pathways, AHREX-101 restores the natural regulatory function of the Aryl Hydrocarbon Receptor (AHR)—a central governance node integrating environmental stress, immune signaling, and metabolic state.

By correcting maladaptive transcriptional bias rather than suppressing biological pathways, AHREX-101 represents a new category of host-directed regulatory therapeutics designed to restore physiological balance.

Development Status: Phase II–Ready

API Class: Single-molecule, biased host-directed modulator

Discovery Logic: Selective Evolutionary Pressure (SEP) inversion

Targeting a Central Regulatory Node: AHR

The Aryl Hydrocarbon Receptor (AHR) has historically been studied primarily as a xenobiotic receptor associated with toxicant exposure.

Emerging systems biology research reveals a broader role: AHR functions as a central stress-integration node coordinating:

• immune signaling
• metabolic regulation
• environmental stress responses
• epithelial barrier integrity

Under chronic biological stress—such as persistent infection or toxicant exposure—AHR signaling can become locked into maladaptive transcriptional states, amplifying immune dysfunction and metabolic instability.

AHREX-101 was designed to restore the natural governance function of AHR while avoiding the toxicant-mimicking behavior associated with classical ligands.

Discovery Through Selective Evolutionary Pressure (SEP)

AHREX-101 originated from the SCF–SEP discovery platform, which identifies therapeutic opportunities by studying how biological systems adapt under selective evolutionary pressures.

Two convergent stress environments informed the discovery logic:

Both conditions produce a similar pathological pattern:

• chronic AHR nuclear occupancy
• CYP-dominant transcriptional bias
• suppression of immune resolution pathways
• metabolic stress amplification

The SEP hypothesis guiding AHREX-101 was that disease emerges when AHR transitions from a stress-conditional regulator into a permanently active adaptation signal.

AHREX-101 is designed to invert this maladaptive pressure by restoring transient, bias-controlled AHR signaling.

Mechanism of Action

AHREX-101 operates through biased, transient modulation of AHR activity, restoring regulatory balance without suppressing normal immune function.

Primary Mechanism

• Partial, bias-controlled activation of AHR
• Suppression of maladaptive xenobiotic transcription
• Restoration of immune-resolution signaling pathways
• Normalization of metabolic stress responses

Secondary Biological Effects

• re-sensitization of immune surveillance mechanisms
• reduction of tolerance-enforcing pathways
• recovery of cellular metabolic efficiency

Importantly, AHREX-101 does not behave like classical AHR ligands.

Molecular Design Strategy

The molecular scaffold of AHREX-101 was engineered to enforce bias and reversibility at the receptor level.

Key design features include:

• non-planar indole-derived scaffold to avoid toxicant mimicry
• partial receptor engagement to prevent saturation
• electronic configuration discouraging prolonged DNA binding
• transient nuclear residency within a circadian window

These design constraints ensure that AHR signaling remains conditional and reversible, consistent with the receptor’s physiological role.

Biomarker-Driven Development

The clinical development strategy for AHREX-101 is anchored in mechanism-linked biomarker monitoring across four biological domains.

Biomarker normalization is expected to precede clinical improvement and persist following drug washout.

Exposure Geometry as a Safety Mechanism

Unlike many therapeutic agents that rely on continuous exposure, AHREX-101 uses pulsatile pharmacologic engagement as a built-in safety mechanism.

Authorized exposure profile

• Oral immediate-release formulation
• Intermittent dosing
• Single circadian signaling window

Explicitly excluded

• sustained-release formulations
• long-acting injectables
• accumulation-driven regimens

This exposure geometry ensures that receptor activation remains transient and physiologically aligned.

Preclinical Profile (Simulated Real-World Analog Data)

Preclinical modeling of AHREX-101 demonstrates:

• partial, transient AHR engagement
• absence of CYP-dominant transcription
• preserved immune competence
• no accumulation under pulsatile dosing
• reversible signaling with washout durability

These characteristics support the host-directed regulatory mechanism central to the SEP design strategy.

Regulatory Differentiation

AHREX-101 represents a new therapeutic category distinct from classical AHR ligands.

This mechanism-anchored approach supports a regulatory strategy focused on safety through reversibility and host-directed modulation.

Platform Implications

AHREX-101 serves as the reference archetype for the SCF–SEP therapeutic discovery platform.

The discovery logic underlying AHREX-101 can be extended to additional targets involved in:

• viral-driven selective pressures
• environmental toxicant convergence nodes
• chronic stress-amplified disease pathways

This platform enables the development of therapeutics that respect biological governance systems rather than overriding them.

A New Direction for Therapeutic Design

AHREX-101 demonstrates how Selective Evolutionary Pressure can be inverted pharmacologically by:

• respecting biology’s temporal signaling rules
• biasing regulatory governance rather than blocking function
• designing safety directly into exposure geometry

The result is a new therapeutic paradigm—adaptive regulatory pharmacology—designed to restore biological balance rather than impose artificial control.

AHREX-101

A First-in-Class Stress-Conditional AHR Governance Modulator

Developed Through the SCF–SEP Therapeutic Discovery Platform

SCF Biotech Systems Therapeutics Program